- Home
- CZNC vs AQST Comparison
CZNC vs AQST Comparison
Compare CZNC & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- AQST
- Stock Information
- Founded
- CZNC 1864
- AQST 2004
- Country
- CZNC United States
- AQST United States
- Employees
- CZNC N/A
- AQST N/A
- Industry
- CZNC Major Banks
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- CZNC Finance
- AQST Health Care
- Exchange
- CZNC Nasdaq
- AQST Nasdaq
- Market Cap
- CZNC 297.0M
- AQST 272.9M
- IPO Year
- CZNC N/A
- AQST 2018
- Fundamental
- Price
- CZNC $20.20
- AQST $3.72
- Analyst Decision
- CZNC
- AQST Strong Buy
- Analyst Count
- CZNC 0
- AQST 6
- Target Price
- CZNC N/A
- AQST $10.67
- AVG Volume (30 Days)
- CZNC 37.1K
- AQST 1.4M
- Earning Date
- CZNC 08-06-2025
- AQST 08-05-2025
- Dividend Yield
- CZNC 5.63%
- AQST N/A
- EPS Growth
- CZNC 15.34
- AQST N/A
- EPS
- CZNC 1.75
- AQST N/A
- Revenue
- CZNC $108,114,000.00
- AQST $54,228,000.00
- Revenue This Year
- CZNC $6.78
- AQST N/A
- Revenue Next Year
- CZNC $4.59
- AQST $45.71
- P/E Ratio
- CZNC $11.39
- AQST N/A
- Revenue Growth
- CZNC 5.33
- AQST 5.29
- 52 Week Low
- CZNC $16.73
- AQST $2.12
- 52 Week High
- CZNC $22.68
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- CZNC 61.43
- AQST 66.35
- Support Level
- CZNC $19.73
- AQST $3.13
- Resistance Level
- CZNC $20.25
- AQST $3.80
- Average True Range (ATR)
- CZNC 0.43
- AQST 0.19
- MACD
- CZNC 0.15
- AQST 0.02
- Stochastic Oscillator
- CZNC 80.56
- AQST 82.09
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.